Allakos Logo

Allakos is a clinical stage biotechnology company that has been developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

  • About
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisors
  • Science
    • Overview
    • Biology
    • Scientific Presentations
  • Clinical
    • Overview
  • Patients
    • Allakos Commitment
    • Chronic Spontaneous Urticaria
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • Financials & Filings
      • SEC Filings
      • Quarterly Reports
      • Annual Reports
    • Stock Information
      • Stock Information
    • Contact
  • Careers
    • Working at Allakos
    • Open Positions
  • Contact
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisors
  • Science
    • Overview
    • Biology
    • Scientific Presentations
  • Clinical
    • Overview
  • Patients
    • Allakos Commitment
    • Chronic Spontaneous Urticaria
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • Financials & Filings
      • SEC Filings
      • Quarterly Reports
      • Annual Reports
    • Stock Information
      • Stock Information
    • Contact
  • Careers
    • Working at Allakos
    • Open Positions
  • Contact
  • Privacy and Cookies Policy
  • Terms of Use
  • Expanded Access Policy
© 2025 Allakos Inc. All rights reserved
Allakos® and the 3-circles design are federally registered trademarks owned by Allakos Inc. Any unauthorized use is expressly prohibited.
Website Design: Hane Chow, Inc.
  • Privacy and Cookies Policy
  • Terms of Use
  • Expanded Access Policy